IL28B is a member of the interferon λ family and is assumed to exhibit its defensive activity against viral infection mediated by similar receptors and intracellular signal transduction pathway as interferon α, which was used in the treatment of hepatitis C. IL28B itself is therefore expected to be a powerful contender for the development of new hepatitis C drugs. This evidence concerns the gene IFNL3 and hepatitis C virus infection.